Akash Tiwari

“I know in the spring, you had a kind of 45-50 patient biomarker analysis on your stat 6, and you were going to make a decision on whether to go from stage 1 to stage 2.”

“Josh, can you go over the moving pieces on the $1.5 billion IRA impact for BICTARB pricing? How much of that is a net pricing impact for Medicare specifically versus the downstream impact on, you know, your kind of Medicaid best price and then the 340B impact?”

“So your team's talked about generally predictable and consistent GLP-1 pricing declines in the U.S. out to the end of the decade. How does that look ex-U.S.? Could we see more stability there than maybe investors expect?”

“Can you frame the AdMilliprant opportunity relative to some of the historical products in the space and also maybe investor expectations around Milvexian or Cabenfi?”

“So, how confident is your team that you can deliver on Vision 2030 post to Sjogren-Smith in the DM update today?”